Pipeline product candidates


PT20 is a novel iron-based phosphate binder that we are developing for the treatment of hyperphosphatemia. The integration of adipic acid to form PT20 increases the phosphate binding capacity by a factor of three, compared to the unmodified iron oxide. The manufacturing process also results in particles of a very small size, which maximises the surface available for phosphate binding.
PT20 is exclusively licensed from the Medical Research Council in the United Kingdom.

PT30 and PT40

PT30 is a novel IV iron formulation and PT40 is being developed to be the first generic version of iron sucrose.

London, UK

16 Upper Woburn Place
London, WC1H 0AF

t+44 (0) 207 186 8500


Newcastle, UK

Northern Design Centre
Baltic Business Quarter
Gateshead Quays, NE8 3DF

t+44 (0) 191 511 8500


Wollerau, Switzerland

Sihleggstrasse 23,
8832 Wollerau

t+41 (0) 435 080 781


Munich, Germany

Oranienburger Str. 3
c/o Lambsdorff Rechtsanwälte PartGmbB
10178 Berlin

t+44 (0) 207 186 8500